{"groups":[{"description":"Patients receive AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nFGFR Inhibitor AZD4547: Given PO","id":"FG000","title":"Treatment (AZD4547)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Never started treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"12"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"25"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Other diseases"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Clinical concerns for progression and increasing tumor marker"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Symptomatic decline"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Pogression of the lymphadenopathy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Clinical progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"50"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"49"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"48"}],"comment":"2 patients ineligible, 1 patient never started treatment, 1 patient both ineligible and never started treatment. This is the primary analysis population.","type":"Eligible and Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"49"}],"comment":"1 of the 50 treated patients had no adverse events reported","type":"Reported Adverse Events Data"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Treatment continued until disease progression or intolerability.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For subprotocol W, patients had to have tumors harboring aberrations in FGFR 1-3.","recruitmentDetails":"Subprotocol W was activated on May 31, 2016. 70 patients were assigned to Subprotocol W after screening, all from screening cohort. Of the 70 patients, 52 patients from 47 different sites enrolled in the study between July 2016 and June 2017."}